Clinical Trial Update: Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a triple combination of olutasidenib, venetoclax, and azacitidine in IDH1-mutated, newly diagnosed acute myeloid leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Olutasidenib (olutasidenib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Justin Watts, MD | Conditions: Acute Myeloid Leukemia, IDH1 Mutation | Phase 2 | Status: RECRUITING